Rivastigmine Study in Adolescents With Down Syndrome (DS-Riv)
A 20-Week Double-Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Rivastigmine in Children (Ages 10-18) With Down Syndrome
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This 24 week, double-blind, placebo controlled trial will be completed at the Clinical Research Unit of Duke University Medical Center and at the Kennedy Krieger Institute (KKI). Sixteen evaluable subjects will be enrolled at Duke and 24 evaluable subjects will be enrolled at KKI. The study consists of four visits, a screening visit (-4 weeks), a baseline visit (week 0); a safety visit at week 10, and a final/termination visit at week 20.
The specific aims of this study are to: a) investigate efficacy of rivastigmine tartrate treatment; b) build upon our open-label treatment results of overall function and language improvement in adolescents with Down syndrome (DS) in a double-blind, placebo-controlled clinical trial; and c) investigate other specific cognitive domains that may selectively respond to rivastigmine tartrate treatment.
The original IRB-approved protocol included the Parent/Caregiver Rating Form of the Vineland Adaptive Behavior Scales- Second Edition (VABS-II) . The protocol was amended to replace the Parent/Caregiver Rating Form of the Vineland Adaptive Behavior Scales- Second Edition (VABS-II) with the Vineland Adaptive Behavior Scales, Second Edition, Survey Interview Form. The protocol was also amended to extend the trial from 12 weeks to 20 weeks. Due to the changes in the amended protocol the subject enrolled prior to the IRB amendment will not be included in the data analysis section.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21205
- Kennedy Krieger Institute
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Duke University Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Correct VERBAL responses for 7/9 of the Expressive One Word Picture Vocabulary Test items.
- Subject able to put at least 2-3 words together in conversational speech.
- Subject's speech is understandable to the examiner for the majority of the time.
- Subjects are in good health and medically stable
Exclusion Criteria:
- Subject uses sign language as a primary means of communication
- Subject has a medical history that contraindicate the use of rivastigmine (For example, patients with active seizure disorders, asthma, celiac disease, heart disease or heart rhythm disorders).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Rivastigmine- Liquid form
At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid.
This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks.
At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks.
If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid.
If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
|
At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid.
This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks.
At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks.
Subjects receiving placebo will maintain the same schedule.
If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid.
If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
Otros nombres:
|
|
Comparador de placebos: Liquid placebo
Subjects receiving placebo will maintain matched titration volume increase as treatment arm.
The placebo will be matched to liquid rivastigmine in consistency and taste.
|
Subjects receiving placebo will maintain matched titration volume increase as treatment arm.
The placebo will be matched to liquid rivastigmine in consistency and taste.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Vineland Adaptive Behavior Scales, Second Edition (Survey Interview Form)
Periodo de tiempo: Baseline & Study termination (Week 20)
|
The Vineland Adaptive Behavior Scales, Second Edition (Survey Interview Form) is a measure of adaptive behavior in children, adolescents and adults.
It yields an overall standard score (Adaptive Behavior Composite, ABC) and age standard scores in four domains.
ABC scores have a mean of 100 and a standard deviation of 15 (range = 20 to 160).
Higher scores suggest a higher level of adaptive functioning.
In this study, the change between each subject's ABC at Baseline and the Final Visit was computed.
A rise in standard scores from Baseline to the Final Visit indicates improvement.
|
Baseline & Study termination (Week 20)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Behavior Rating Inventory of Executive Function-Preschool (BRIEF-P)
Periodo de tiempo: Baseline and Final (Week 20) visit
|
The Behavior Rating Inventory of Executive Function-Preschool Version (BRIEF-P) is a parent report measure of executive function behaviors in children in their home setting.
It yields an overall score (Global Executive Composite, GEC) that is based on its five clinical scales.
Raw scores range from 63 to 189.
Higher scores suggest that an individual's executive function skills are more problematic.
In this study, the change between each subject's raw score at Baseline and the Final Visit was computed for the Global Executive Composite.
A decline in raw scores from Baseline to the Final Visit indicates improvement.
|
Baseline and Final (Week 20) visit
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: George Capone, MD, Kennedy Krieger Institute/Johns Hopkins
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedades del Sistema Nervioso
- Manifestaciones neurológicas
- Manifestaciones neuroconductuales
- Enfermedad
- Anomalías congénitas
- Enfermedades Genéticas Congénitas
- Discapacidad intelectual
- Anomalías Múltiples
- Trastornos cromosómicos
- Síndrome
- Síndrome de Down
- Efectos fisiológicos de las drogas
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Agentes colinérgicos
- Inhibidores de enzimas
- Agentes neuroprotectores
- Agentes Protectores
- Inhibidores de la colinesterasa
- Rivastigmina
Otros números de identificación del estudio
Otros números de identificación del estudio
- Pro00013682
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .